Healthcare Industry News: Plasmin
News Release - November 18, 2009
EKOS Corporation Launches the New EkoSonic(TM) MACH4e at VEITHsymposium in New YorkNo Limits to Treating Thrombus
NEW YORK--(HSMN NewsFeed)--Today EKOS Corporation launched the EkoSonic(TM) MACH4e with Rapid Pulse Modulation (RPM) for the dissolution of vascular blood clots at the 36th Annual VEITHsymposium in New York.
Robert W. Hubert, President and CEO of EKOS Corporation, said, “We continue to listen to our customers in assessing how we can further improve the performance and simplicity of operation. The MACH4e upgrade addresses both categories. For performance, we have achieved even faster removal of arterial and venous clots (accelerating thrombolysis speed by up to 40%), making it even faster than the MACH4. For simplicity, we have automated a number of manual steps, making the system easier to use; the control unit is much smarter. A world-class vascular innovation forum like the VEITHsymposium is the ideal event at which to launch the MACH4e.”
Providers can “EKOS IT ANYWHERE” in the periphery, including:
- Veins, arteries, IVC filters and difficult-to-reach places such as behind valves, and exposes clot to a greater drug uptake
- Thrombus of any size, shape, volume and age can be treated with less lab time
- Uses 50% - 70% less lytic drug, no thrombus fracture or breakage, reducing the risk of distal embolism
- No hemolysis, no damage to valves or vascular wall
- A higher level of vessel patency. Removes the thrombus more completely, possibly reducing the risk of Post-Thrombotic Syndrome (PTS)
EKOS Corporation pioneered the development and clinical application of ultrasonic accelerated drug delivery in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions around the world use the EKOS EkoSonic Endovascular System to provide faster, safer and more complete dissolution of thrombus. In 2008, the company introduced its 2nd-generation EkoSonic(TM) Endovascular System with Rapid Pulse(TM) Modulation, and in 2009 introduced the MACH4e upgrade. The EkoSonic System is FDA-cleared for controlled and selective infusion of physician-specified fluids, including thrombolytic, into the peripheral vasculature. It is currently used to treat patients with peripheral arterial occlusions (PAO) and deep vein thrombosis (DVT) and additional applications are being investigated. EKOS is currently participating in the ATTRACT trial, which will evaluate the long-term benefits of using ultrasound catheter-directed thrombolysis for removal of clot. Visit www.ekoscorp.com.
Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world-renowned vascular specialists, with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Additional information can be found at www.VEITHpress.org.
1 EKOS in vitro data on file
2 Francis, CW, eta al. “Ultrasound Accelerates Transport of Recombinant tissue Plasminogen Activator into Clots.” Phys Med Biol, 2008+
3 Parikh, S., et al. “Ultrasound-Accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience.” Journal of Vascular and Interventional Radiology, April 2008, 19:4, pp521-528.1
4 Braatan, J., et al. “Ultrasound Reversibly Disaggregates Fibrin Fibers.” Thromb Haemost 78 (1997) 1063-8.4
Source: EKOS Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.